TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
NCT01204749
Completed
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Research Site, Phoenix, Arizona +224 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Register for Updates
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
NCT00003582
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy and chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy and amifostine in treating patients who have stage II, stage III, or stage IV hea... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/14/2016
Locations: Sylvester Cancer Center, University of Miami, Miami, Florida
Conditions: Carcinoma of Unknown Primary, Head and Neck Cancer
Register for Updates
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
NCT00073723
Completed
The anticancer agent paclitaxel (Taxol for Injection Concentrate, Bristol-Meyers Squibb) has a broad spectrum of activity against several human cancers including carcinomas of ovary, breast, lung, esophagus and head and neck cancer. Taxol has shown remarkable activity against metastatic breast cancer, yielding response rates in the range of 40% to 60% in chemotherapy-naive patients and 25%-30% in patients refractory to anthracycline-containing regimens (Taxol package insert). The major limitatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
NCT00062062
Completed
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with carboplatin and paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib alone or together with carboplatin and paclitaxel works in treating older patie... Read More
Gender:
ALL
Ages:
Between 65 years and 120 years
Trial Updated:
12/12/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +140 locations
Conditions: Lung Cancer
Register for Updates
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
NCT00314678
Completed
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan. As expected, myelosuppression was the dose-limiting factor. Herben et al recently reported the results of a phase I trial using the combination of paclitaxel, cisplatin, and topotecan as first line therapy in advanced stage ovarian cancer. Interestingly, the authors could not achieve a dose of topotecan that would be... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/06/2016
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Register for Updates
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00022139
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy and giving them before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: This phase II trial is studying how well giving radiation therapy together with combination chemotherapy followe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Cancer Center of Kansas, PA - Chanute, Chanute, Kansas +34 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
NCT01555853
Terminated
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: St. Louis University School of Medicine, St. Louis, Missouri +1 locations
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00032032
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +50 locations
Conditions: Lung Cancer
Register for Updates
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
NCT00046423
Completed
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/23/2016
Locations: Abraxis Bioscience, Inc., Durham, North Carolina
Conditions: Neoplasms, Metastases, Neoplasm
Register for Updates
Reirradiation With Concurrent Paclitaxel for Breast Cancer
NCT02058667
Withdrawn
The purpose of this trial in addition to a dose finding study for concurrent Paclitaxel, will be to establish a treatment algorithm for chest wall reirradiation. A nominal margin of at least 5cm will be used on the protocol and extending it to 7cm. Considering the standard treatment of breast cancer incorporates a cumulative dose of 60Gy, delivering an additional 50.4 Gy followed by a boost should target a total dose of 120 Gy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2016
Locations: Markey Cancer Center, Lexington, Kentucky
Conditions: Breast Cancer
Register for Updates
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01254526
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with taxane-based chemotherapy regimens utilized in patients with locally recurrent or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT00974584
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Buffalo, New York +2 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates